Skip to content

Repair and pain · part of Injury, healing and recovery

Peptides for tendon healing

Does it heal a tendon faster?

The claim BPC-157 is sold on. Check how much of the evidence under it was measured in a person rather than a rat.

14

compounds on this page

0

trials in people, anywhere

3

compounds, animal or lab only

12

compounds people report on

No trial in people

Nobody has run a proper trial in people for tendon, ligament and injury healing on anything in this archive.

That is a fact about which trials exist. It is not a failed test. Nothing here has been tested and failed. The question is still open. The rest of this page is what does exist: what people using these compounds report, the animal and lab work, and why the trial in people was never run.

What people using these actually report

These are people describing their own use. They come from clinic write-ups, complaint records kept by regulators, and public forums, and they are shown as written. They are the best guide on this page to what people actually do, what they expect, and what goes wrong. They cannot show that anything works. Nobody was compared with people on a dummy pill, and people who saw no effect mostly stopped posting. Both things are true at once. The bad reports are kept in for the same reason.

BPC-157
  • People say they use it for tendon pain, mostly elbow, shoulder and Achilles, for partly torn muscles, for knee pain and after surgery. Some use it for gut trouble such as reflux and bowel swelling.
  • The usual story is less pain in the first one to two weeks, then the joint or tendon handling more load by weeks three to six. People who stop before about four weeks often say nothing lasted.
  • Some people report new or worse tendon or joint pain while taking it. These reports are much rarer than reports of relief. No published study has looked for this on purpose.

Sources: FDA's July 2026 evaluation of BPC-157, which reproduces the FAERS side-effect reports through December 4, 2025, the Human Foods Program complaint records, and the marketed dosage forms and strengths; the three published clinic reports above, which are the only documented clinical practice; the 2025 HSS Journal systematic review and the 2026 American Journal of Sports Medicine and Sports Medicine reviews, which describe how athletes and clinicians are using these peptides and note that indications, dosing, frequency and duration all remain undefined; and public injury logs and question threads on peptide and bodybuilding forums including eroids, iSARMS, Ironsport and FITMISC. Reddit's r/Peptides and r/PeptideSupport could not be retrieved for this entry, so nothing above is attributed to any specific post, and no quotation is reproduced from any of these sources.

TB-500
  • People say they use it for long-lasting tendon and ligament problems, shoulder and hip trouble, scar tissue and stiffness, and general recovery between hard training blocks.

Sources: FDA's July 2026 evaluation of TB-500, including its FAERS search, its catalogue of vendor claims and its account of the veterinary preparation; the 2012 Ghent doping-control identification paper; the 2026 Sports Medicine and American Journal of Sports Medicine reviews on how these peptides are used and marketed; and public discussion and injury logs on peptide and bodybuilding forums including eroids, iSARMS, Ironsport and FITMISC, where TB-500 is almost always logged alongside BPC-157. Reddit's r/Peptides and r/PeptideSupport could not be retrieved for this entry. No quotation is reproduced from any of these sources and nothing above is attributed to a specific person.

Thymosin Beta-4
  • Where people report improvement it is for a joint or tendon problem, described as beginning within the first few injections and as clearer after about a week, and it is almost always described alongside BPC-157 rather than on its own, which makes attribution impossible.

Sources: Peptide and injury threads on ExcelMale, plus a long-running safety thread on LongeCity, found by site-restricted search and read in September 2026. Nothing above is attributed to any specific post and no post is reproduced.

KLOW blend
  • Less joint and tendon pain in the first few weeks, described the same way people describe BPC-157 on its own.

Sources: Peptide and bodybuilding forums including r/peptides, clinic write-ups and vendor testimonial pages. These are uncontrolled self-reports, usually from people running other things at the same time, frequently including a topical copper serum. They are recorded here as reports and are not evidence of effect. The FDA side-effect material referenced above comes from the agency's 2026 BPC-157 evaluation cited on this page.

GLOW blend
  • Nagging tendon or joint pain easing, described the same way people describe BPC-157 alone.

Sources: Peptide and skincare forums including r/peptides, clinic write-ups and vendor testimonial pages. No trial of this blend exists, so none of this comes from trial exit interviews or an side-effect table for the product. Most people posting are using a topical copper product at the same time as the injection, which makes attribution impossible even within the report. The FDA side-effect material comes from the agency's 2026 BPC-157 evaluation cited on this page.

Resveratrol
  • The most common complaint at higher doses, about 500 mg and up, is loose or soft stools. A smaller number of posts describe joint or tendon aches starting at a few hundred milligrams. Nothing like that shows up in the trials, so read it as an unconfirmed, single-source kind of report, not a known side effect.

Sources: LONGECITY's Resveratrol subforum (including a long-running 'Positive, Negative, ZERO, effect noticed?' poll thread and a dedicated side-effects thread), general web search of longevity-community and vendor commentary on dosing, form and piperine practice, and Peter Attia's public podcast and written statements. Direct access to r/longevity, r/Supplements and r/Biohackers on Reddit was not available in this research pass (Reddit pages could not be fetched and did not surface in general web search here), so those specific subreddits could not be independently checked and any overlap with the sentiment described above is inferred, not confirmed firsthand.

Nandrolone decanoate
  • The most important recurring caution is that relief is masking rather than repair. Moderators make the point repeatedly that cartilage and tendon damage is still there, and that the predictable sequence is feeling better, training harder because strength is up, and re-injuring the same joint.

Sources: Nandrolone and TRT threads on ExcelMale, including a mood poll thread, found by site-restricted search and through the site's tag index, read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

Wolverine blend
  • Feeling like soft tissue injuries heal faster, most often tendon and shoulder problems. People usually report this during stretches when they were also resting and doing rehab.

Sources: Peptide and bodybuilding forums, vendor testimonial pages and clinic write-ups. These are uncontrolled self-reports from people who were usually also resting and rehabilitating an injury, and they are recorded here as reports, not as findings.

Deadpool blend
  • Less tendon and joint pain in the first few weeks, described the same way people describe BPC-157 alone.

Sources: Peptide forums including r/peptides, vendor product pages and price-comparison listings. Uncontrolled self-reports from people usually running other compounds at the same time. Recorded as reports, not evidence.

BPC-157 with KPV
  • Joint and tendon pain getting better as a bonus, which people credit to the BPC-157.

Sources: Peptide and inflammatory bowel forums, clinic write-ups and vendor testimonial pages. Uncontrolled, usually alongside diet changes and other supplements. Reports, not evidence.

PDA with TB-500
  • Tendon and joint pain getting better over two to six weeks.

Sources: Peptide forums including r/peptides, clinic write-ups and vendor pages. Uncontrolled self-reports. The sting comparison in particular is unblinded and the two products look different in the vial.

Quad healing blend
  • Joint and tendon relief in the first weeks.

Sources: Clinic write-ups, vendor listings and peptide forums. Uncontrolled self-reports, frequently alongside other compounds. Reports, not evidence.

Measured in animals or in the lab, not yet in people

These are kept apart from the studies in people, not ranked against them. They answer a different question. A result in a rat is a real result, and a reason somebody ran the study. It is not a measure of what happens in you. When the work in people is missing, the reason is usually money, not failure. The bottom of this page explains why.

Peptides and blends

  1. 01BPC-157PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 31 people given it.10 reported
    1 animal or lab study

    What people using it report

    • People say they use it for tendon pain, mostly elbow, shoulder and Achilles, for partly torn muscles, for knee pain and after surgery. Some use it for gut trouble such as reflux and bowel swelling.
    • The usual story is less pain in the first one to two weeks, then the joint or tendon handling more load by weeks three to six. People who stop before about four weeks often say nothing lasted.
    • Some people report new or worse tendon or joint pain while taking it. These reports are much rarer than reports of relief. No published study has looked for this on purpose.

    Measured in animals or in the lab

    • In rats with a cut Achilles tendon, a daily dose of BPC-157 made the healing tendon stronger than salt water did. The rats also walked better, and more collagen, the tendon's building protein, formed.

      The numbers In rats with transected Achilles tendon, daily BPC 157 improved biomechanical load to failure, functional index scores and collagen formation versus saline.

      Journal of Orthopaedic Research, 2003· animal study

  2. 02CartalaxPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 4 lab studies, no human study.8 reported
    1 animal or lab study

    Measured in animals or in the lab

    • In a dish. Stem cells from the tissue that holds teeth in place were exposed to four short peptides. Signs of young nerve cells went up with the mix of all four, and with one of the other peptides. The authors do not report that effect for Cartalax on its own.

      The numbers Human periodontal ligament stem cells exposed to AED, KED, Lys-Glu and AEDG. The combination of all four peptides and KED alone raised GAP-43 and nestin expression. Notably the effect the authors highlight is for KED and for the mixture, not for AED on its own, and the setting is cell culture.

      International Journal of Immunopathology and Pharmacology, 2019· lab (cells in a dish)

Other compounds

  1. 01UBX0101Small moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 183 people given it.3 reported
    1 animal or lab study

    Measured in animals or in the lab

    • In mice. In mice bred so worn-out cells could be tracked and killed, clearing worn-out cells after a knee ligament injury eased arthritis and pain and helped cartilage grow. A clean-up drug injected into the knee did the same in normal and old mice. Cells from people having knee replacements were treated in a dish, not in the people.

      The numbers Mouse. Using the p16-3MR transgenic model after anterior cruciate ligament transection, selective elimination of senescent cells attenuated post-traumatic osteoarthritis, reduced pain and increased cartilage development, reproduced by intra-articular injection of a senolytic molecule in transgenic, non-transgenic and aged mice. Cells from patients undergoing knee replacement were treated in culture, not in the patients.

      Nature Medicine, 2017· animal study

Why the trial record looks like this

A missing trial usually means nobody would pay for it. Nobody spends hundreds of millions of dollars on a molecule they cannot own. So the compounds with the thinnest record in people are often the oldest and easiest to get, not the weakest. Taking BPC-157 as the example, because it states the problem most clearly:

The thin record in people makes more sense once you ask who would pay for a bigger one. BPC-157's recipe of 15 amino acids has been public since the early 1990s, so no company can own it. A company could spend a fortune on a large final-stage study, and a compounding pharmacy or a research chemical seller could sell the same peptide the week it was approved. The one company that did test it in people, Pliva in Croatia, ran an early safety test and a 53-patient study under the code PL 14736 in the early 2000s. Then it stopped. The 2026 Pharmaceutics review says the same thing from the drug making side. What is missing is not proof that it does something in the body. What is missing is the basic work of making it a drug: a set formula, measured blood levels in people, and a plan.

Thymosin beta-4 shows what money buys. It had a company behind it, RegeneRx, and a partner, ReGenTree, that made its own eye drop. They paid for the full set of studies: an early test, several mid-sized studies, and three large dry eye studies in 317, 601 and 700 patients. The money bought answers, not good news. The two biggest studies missed the main goals they were built to hit. A paid-for program is how you find out. An unpaid one leaves the question open. That is not a no. It is not a yes either.

The July 2026 vote sits right on that line. In a May 11, 2026 memo, the FDA's reviewers advised against adding BPC-157 to the 503A list, the list of ingredients compounding pharmacies may use. They gave four reasons. One: it is not well defined. Several salt forms are sold under one name, and it has no official US name or standard. Two: nobody has checked whether the immune system reacts to it, which matters for a peptide people inject again and again. Three: the evidence does not show it works for ulcerative colitis, the use it was put forward for. Four: approved drugs for ulcerative colitis already exist. The panel voted 8 to 6, with one person not voting, to back it anyway. Supporters said no studies is not the same as proof it fails. They also said a regulated pharmacy route is safer than the gray market for people who will buy it no matter what. Opponents, some of them on the record, said a peptide with no proof it works should not get a legal channel. Two of the FDA's four objections are about what kind of product it is and how well it is made. A manufacturing standard could fix those without a single new study. The third is about evidence, and it is specific. Nobody has tested BPC-157 for ulcerative colitis in the way anyone plans to use it. Nobody has tested it with a dummy group for the injuries most people buy it for. The vote is only advice. The FDA has to act to add it to the list, and until then the legal status stays the same.

Read this on the BPC-157 profile

Every goal we track Combine this with other goals in the finder

A compound shows up here only when a study on its own page names this goal and reports a result for it. Just naming it is not enough. Work in people, in animals and in the lab is counted separately and never mixed. People counts come from the study lines, and when in doubt they count low. Nothing here is advice. Nothing here tells you to take or to avoid anything.